| Patents for A61K 39 - Medicinal preparations containing antigens or antibodies (182,248) |
|---|
| 01/08/2013 | US8349333 Allergy inhibitor compositions and kits and methods of using the same |
| 01/08/2013 | US8349332 Multiple signaling pathways induced by hexavalent, monospecific and bispecific antibodies for enhanced toxicity to B-cell lymphomas and other diseases |
| 01/08/2013 | US8349331 Anti-interferon-α antibodies |
| 01/08/2013 | US8349330 Therapeutic use of anti-CS1 antibodies |
| 01/08/2013 | US8349329 Antibodies that bind to PRO286 |
| 01/08/2013 | US8349327 Method for treating muscular dystrophy using antagonist antibodies against GDF-8 |
| 01/08/2013 | US8349326 Methods and systems for multi-antibody therapies |
| 01/08/2013 | US8349325 Soluble FMS-like tyrosine kinase-1 (sFLT-1) antibody and related composition, kit, methods of using, and materials and method for making |
| 01/08/2013 | US8349324 Methods of humanizing immunoglobulin variable regions through rational modification of complementarity determining residues |
| 01/08/2013 | US8349323 Cytokine antagonists for neurological and neuropsychiatric disorders |
| 01/08/2013 | US8349322 Stable and soluble antibodies inhibiting VEGF |
| 01/08/2013 | US8349321 Immunoglobulin formulation and method of preparation thereof |
| 01/08/2013 | US8349320 Compositions and methods for modulating responses mediated or associated with BTLA activity |
| 01/08/2013 | US8349318 Use of specifically engineered enzymes to enhance the efficacy of prodrugs |
| 01/08/2013 | US8349292 Treatment of allergic otitis media in mammals with Clostridia neurotoxins |
| 01/08/2013 | CA2584249C Methods and compositions for combinatoral-based production of multivalent recombinant antigens |
| 01/08/2013 | CA2579710C Antigen-drug vehicle enabling transmucosal and transdermal administration, and method of inducing mucosal immunity and mucosal vaccine and dds using the same |
| 01/08/2013 | CA2574881C Antibodies to dkk-1 |
| 01/08/2013 | CA2531118C Multivalent carriers of bi-specific antibodies |
| 01/08/2013 | CA2514667C Adjuvanted influenza vaccine |
| 01/08/2013 | CA2492930C Vaccine compositions containing amyloid beta1-6 antigen arrays |
| 01/08/2013 | CA2489004C Agonistic binding molecules to the human ox40 receptor |
| 01/08/2013 | CA2470262C Glycoconjugates and their use as potential vaccines against infection by shigella flexneri |
| 01/08/2013 | CA2457541C Methods for the identification of polypeptide antigens associated with disorders involving aberrant cell proliferation and compositions useful for the treatment of such disorders |
| 01/08/2013 | CA2457441C Infectious and attenuated bovine viral diarrhea virus clone; methods for their production and use |
| 01/08/2013 | CA2454361C Humanized antibodies |
| 01/08/2013 | CA2441577C Therapeutic agents for inflammatory bowel diseases |
| 01/08/2013 | CA2409873C Hcv variants |
| 01/08/2013 | CA2390095C Method and system to remove cytokine inhibitor in patients |
| 01/08/2013 | CA2388337C Method of inducing and/or enhancing an immune response to tumor antigens |
| 01/08/2013 | CA2346497C Spodoptera frugiperda single cell suspension cell line in serum-free media, methods of producing and using |
| 01/08/2013 | CA2341777C Neutral amino acid transporter and gene thereof |
| 01/08/2013 | CA2341352C Oral vaccine compositions |
| 01/08/2013 | CA2317727C Multipurpose antibody derivatives |
| 01/08/2013 | CA2305681C Apoptosis-related compounds and their use |
| 01/08/2013 | CA2299630C Compositions that specifically bind to colorectal cancer cells and methods of using the same |
| 01/08/2013 | CA2223608C Vaccine for porcine reproductive and respiratory syndrome virus |
| 01/08/2013 | CA2221511C Vaccine comprising a polysaccharide antigen-carrier protein conjugate and free carrier protein |
| 01/08/2013 | CA2216139C Recombinant infectious laryngotracheitis virus and uses thereof |
| 01/03/2013 | WO2013003786A1 Use of pertussis toxin as a therapeutic agent |
| 01/03/2013 | WO2013003761A1 Inhibitors of t-cell activation |
| 01/03/2013 | WO2013003680A1 Anti-c-met antibody formulations |
| 01/03/2013 | WO2013003649A2 Wap domain fusion polypeptides and methods of use thereof |
| 01/03/2013 | WO2013003647A2 Multispecific stacked variable domain binding proteins |
| 01/03/2013 | WO2013003641A2 Serpin fusion polypeptides and methods of use thereof |
| 01/03/2013 | WO2013003624A2 The capture, purification and release of biological substance using a surface coating |
| 01/03/2013 | WO2013003606A1 Predictive biomarker of survival in the treatment of renal cell carcinoma |
| 01/03/2013 | WO2013003579A1 Cytotoxic t-lymphocyte-inducing immunogens for prevention, treatment, and diagnosis of dengue virus infection |
| 01/03/2013 | WO2013003037A2 Dosage and administration of anti-erbb3 antibodies in combination with paclitaxel for treatment of gynecological cancers |
| 01/03/2013 | WO2013002485A2 Pharmaceutical composition for preventing and treating kidney disorders, containing inhibitor for phosphorylation of taz tyrosine as active ingredient for activation of nfat5/tonebp |
| 01/03/2013 | WO2013002449A1 Epitope and its use of hepatitis b virus surface antigen |
| 01/03/2013 | WO2013002362A1 Heterodimerized polypeptide |
| 01/03/2013 | WO2013001819A1 SOLUBLE INTEGRIN α4 MUTANT |
| 01/03/2013 | WO2013001369A2 Therapeutic and diagnostic target |
| 01/03/2013 | WO2013001295A1 Neisserial compositions and expression constructs |
| 01/03/2013 | WO2013001285A2 Peptide |
| 01/03/2013 | WO2013001124A1 Saccharide nanocompositions for vaccine release |
| 01/03/2013 | WO2013001080A1 Composition comprising inhibitors of irs-1 and of vegf |
| 01/03/2013 | WO2013000980A1 Recombinant mistletoe lectin and use thereof as an adjuvant |
| 01/03/2013 | WO2013000905A1 Canine coronavirus vaccine |
| 01/03/2013 | WO2013000876A1 An aqueous composition comprising a biological antigen and an acrylic acid polymer |
| 01/03/2013 | WO2013000471A1 Therapeutic targeting of ficolin-3 |
| 01/03/2013 | WO2012170607A3 Use of pcsk9 antagonists |
| 01/03/2013 | WO2012154311A3 Focused evolution of hiv-1 neutralizing antibodies revealed by crystal structures and deep sequencing |
| 01/03/2013 | WO2012151391A3 Inactivated swine flu virus and methods of preparing it |
| 01/03/2013 | WO2012149255A3 Tolerogenic synthetic nanocarriers to reduce immune responses to therapeutic proteins |
| 01/03/2013 | WO2012149247A3 Tolerogenic synthetic nanocarrier compositions with transplantable graft antigens and methods of use |
| 01/03/2013 | WO2012143524A3 Bispecific antibodies against her2 and cd3 |
| 01/03/2013 | WO2012140127A3 Method for priming of t cells |
| 01/03/2013 | WO2012138880A9 Methods of treating inflammatory diseases by targeting the chemoattractant cytokine receptor 2 (ccr2) or chemokine (c-c motif) ligand 2 (ccl2) |
| 01/03/2013 | WO2012135695A3 Modulation of cellular migration |
| 01/03/2013 | WO2012118863A9 Therapies that target autoimmunity for treating glaucoma and optic neuropathy |
| 01/03/2013 | WO2012109553A3 Ch2 domain template molecules derived from rational grafting of donor loops onto ch2 scaffolds |
| 01/03/2013 | WO2011121559A3 Stabilized antibody preparations and uses thereof |
| 01/03/2013 | WO2009095796A3 Tapasin augmentation for enhanced immune response |
| 01/03/2013 | US20130007926 Administration of plant expressed oral tolerance agents |
| 01/03/2013 | US20130006034 Methods of enhancing the response to radiation in tumor therapy using anti-dll4 antibodies |
| 01/03/2013 | US20130005668 Nucleic acids and corresponding proteins entitled 158p3d2 useful in treatment and detection of cancer |
| 01/03/2013 | US20130004977 Measuring circulating therapeutic antibody, antigen and antigen/antibody complexes using elisa assays |
| 01/03/2013 | US20130004579 Use of Plant Lectins to Target Leukocytes |
| 01/03/2013 | US20130004574 Combination pharmaceutical composition and methods of treating functional diseases or conditions of gastrointensinal tract |
| 01/03/2013 | US20130004561 Therapies for preventing or suppressing clostridium difficile infection |
| 01/03/2013 | US20130004547 Oral vaccines produced and administered using edible micro-organisms including lactic acid bacterial strains |
| 01/03/2013 | US20130004539 Methods for preventing and treating staphylococcus aureus colonization, infection, and disease |
| 01/03/2013 | US20130004538 Methods and compositions for modulating an immune response with immunogenic oligonucleotides |
| 01/03/2013 | US20130004537 BACTERIUM COMPRISING A REGULATED rfaH NUCLEIC ACID |
| 01/03/2013 | US20130004536 Multiple vaccination including serogroup c meningococcus |
| 01/03/2013 | US20130004535 Multiple vaccination including serogroup c meningococcus |
| 01/03/2013 | US20130004534 Inactivation of reverse transcriptases by azido-diarylpyrimidines |
| 01/03/2013 | US20130004532 Process for manufacturing vaccines |
| 01/03/2013 | US20130004531 Immunogens from uropathogenic escherichia coli |
| 01/03/2013 | US20130004530 Vaccine composition |
| 01/03/2013 | US20130004529 Vaccines and methods for using the same |
| 01/03/2013 | US20130004528 Direct analysis of antigen-specific immune response |
| 01/03/2013 | US20130004527 Contiguous overlapping peptides for treatment of ragweed pollen allergy |
| 01/03/2013 | US20130004525 Inactivating pathogens with oxidizing agents for vaccine production |
| 01/03/2013 | US20130004524 Conjugated Proteins |
| 01/03/2013 | US20130004523 Therapeutic compositions and methods for delivery of active agents cleavably linked to nanoparticles |
| 01/03/2013 | US20130004522 Phototriggered nanoparticles for cell and tissue targeting |
| 01/03/2013 | US20130004521 Targeting cancer stem cells |